The High Throughput Screening (HTS) and Chemical Synthesis (CS) Shared Resource provides state-ofthe- art capability for Vanderbilt-lngram Cancer Center (VICC) researchers to harness the power of HTS/CS to support target discovery, pathway mapping, chemical tool discovery, and exploratory preclinical drug discovery research. HTS/CS includes a chemical library of >170,0000 small molecules, advanced liquid handling, and a broad array of signal detecfion modalifies enabling researchers to address quesfions spanning from protein-protein interactions in purified cell-free systems to colony formation and morphology assays using automated imaging. The facility has the capability of addressing all commonly used opfical techniques (fluorescence, luminscense, kinefic imaging, high-content imaging, scinfillation proximity, refractive index spectroscopy (Corning Epic), automated electrophysiology, and very shortly in collaboration with Stephen Fesik, Ph.D. fragment-based NMR approaches). The complementary CS resource provides an ability to apply advanced chemical synthesis and medicinal chemistry methodologies including solution-phase parallel synthesis, microwave assisted catalysis, automated mass-directed purification, and both chiral synthesis and purificafion resources. HTS/CS employs a highly trained staff of HTS experts who work directly with Vanderbilt investigators to develop, implement, and interpret HTS. This team works hand-in-hand with the team in the CS facility to help investigators extract maximum value from the shared resource by providing a mechanism to use medicinal chemistry techniques to understand, improve, and ufilize HTS hits. David Weaver, Ph.D., directs the HTS component and Alex Waterson, Ph.D., directs the CS portion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-18
Application #
8733542
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
$180,339
Indirect Cost
$89,303
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Pannala, Venkat R; Wall, Martha L; Estes, Shanea K et al. (2018) Metabolic network-based predictions of toxicant-induced metabolite changes in the laboratory rat. Sci Rep 8:11678
Salisbury-Ruf, Christi T; Bertram, Clinton C; Vergeade, Aurelia et al. (2018) Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study. Elife 7:
Laroumanie, Fanny; Korneva, Arina; Bersi, Matthew R et al. (2018) LNK deficiency promotes acute aortic dissection and rupture. JCI Insight 3:
Doxie, Deon B; Greenplate, Allison R; Gandelman, Jocelyn S et al. (2018) BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res 31:708-719
Phelps, Hannah M; Al-Jadiry, Mazin F; Corbitt, Natasha M et al. (2018) Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq. World J Pediatr 14:585-593
Liu, Qi; Herring, Charles A; Sheng, Quanhu et al. (2018) Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biol 16:e2006687
Burns, Michael C; Howes, Jennifer E; Sun, Qi et al. (2018) High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Anal Biochem 548:44-52
Greenplate, Allison; Wang, Kai; Tripathi, Rati M et al. (2018) Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies. JCO Precis Oncol 2018:

Showing the most recent 10 out of 2462 publications